CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2017 Mar 23

PMID 28326306

Citations 361

Authors

Linda T Senbanjo

Meenakshi A Chellaiah

Affiliations

Soon will be listed here.

Abstract

CD44 is a cell surface adhesion receptor that is highly expressed in many cancers and regulates metastasis via recruitment of CD44 to the cell surface. Its interaction with appropriate extracellular matrix ligands promotes the migration and invasion processes involved in metastases. It was originally identified as a receptor for hyaluronan or hyaluronic acid and later to several other ligands including, osteopontin (OPN), collagens, and matrix metalloproteinases. CD44 has also been identified as a marker for stem cells of several types. Beside standard CD44 (sCD44), variant (vCD44) isoforms of CD44 have been shown to be created by alternate splicing of the mRNA in several cancer. Addition of new exons into the extracellular domain near the transmembrane of sCD44 increases the tendency for expressing larger size vCD44 isoforms. Expression of certain vCD44 isoforms was linked with progression and metastasis of cancer cells as well as patient prognosis. The expression of CD44 isoforms can be correlated with tumor subtypes and be a marker of cancer stem cells. CD44 cleavage, shedding, and elevated levels of soluble CD44 in the serum of patients is a marker of tumor burden and metastasis in several cancers including colon and gastric cancer. Recent observations have shown that CD44 intracellular domain (CD44-ICD) is related to the metastatic potential of breast cancer cells. However, the underlying mechanisms need further elucidation.

Citing Articles

Development and Characterization of CD44-Targeted X-Aptamers with Enhanced Binding Affinity for Cancer Therapeutics.

Wang H, He W, Elizondo-Riojas M, Zhou X, Lee T, Gorenstein D Bioengineering (Basel). 2025; 12(2).

PMID: 40001633 PMC: 11852163. DOI: 10.3390/bioengineering12020113.

Non-Animal Hyaluronic Acid and Probiotics Enhance Skin Health via the Gut-Skin Axis: An In Vitro Study on Bioavailability and Cellular Impact.

Galla R, Mule S, Ferrari S, Molinari C, Uberti F Int J Mol Sci. 2025; 26(3).

PMID: 39940667 PMC: 11817077. DOI: 10.3390/ijms26030897.

Effects of Hyaluronic Acid on Three Different Cell Types of the Periodontium in a Novel Multi-Culture Cell Plate: An Exploratory Study.

Barbieri A, Pitzurra L, Loos B, Jansen I Biomolecules. 2025; 15(1).

PMID: 39858546 PMC: 11764015. DOI: 10.3390/biom15010152.

Hyaluronic Acid-Based Drug Delivery Systems for Cancer Therapy.

Pashkina E, Bykova M, Berishvili M, Lazarev Y, Kozlov V Cells. 2025; 14(2).

PMID: 39851489 PMC: 11764402. DOI: 10.3390/cells14020061.

Advanced photoluminescent nanomaterials for targeted bioimaging of cancer cells.

Mohammadi T, Gheybalizadeh H, Rahimpour E, Soleymani J, Shafiei-Irannejad V Heliyon. 2025; 11(1):e41566.

PMID: 39850435 PMC: 11754178. DOI: 10.1016/j.heliyon.2024.e41566.

References

Louderbough J, Schroeder J . Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011; 9(12):1573-86. DOI: 10.1158/1541-7786.MCR-11-0156. View

Samanna V, Wei H, Ego-Osuala D, Chellaiah M . Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res. 2006; 312(12):2214-30. DOI: 10.1016/j.yexcr.2006.03.022. View

Akech J, Wixted J, Bedard K, van der Deen M, Hussain S, Guise T . Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2009; 29(6):811-21. PMC: 2820596. DOI: 10.1038/onc.2009.389. View

Seiter S, ARCH R, Reber S, Komitowski D, Hofmann M, Ponta H . Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993; 177(2):443-55. PMC: 2190906. DOI: 10.1084/jem.177.2.443. View

Yu Q, Stamenkovic I . Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999; 13(1):35-48. PMC: 316376. DOI: 10.1101/gad.13.1.35. View

Goodison S, Urquidi V, Tarin D . CD44 cell adhesion molecules. Mol Pathol. 2000; 52(4):189-96. PMC: 395698. DOI: 10.1136/mp.52.4.189. View

Orian-Rousseau V, Chen L, Sleeman J, Herrlich P, Ponta H . CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002; 16(23):3074-86. PMC: 187488. DOI: 10.1101/gad.242602. View

Miletti-Gonzalez K, Murphy K, Kumaran M, Ravindranath A, Wernyj R, Kaur S . Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem. 2012; 287(23):18995-9007. PMC: 3365933. DOI: 10.1074/jbc.M111.318774. View

Gunthert U, Stauder R, Mayer B, Terpe H, Finke L, Friedrichs K . Are CD44 variant isoforms involved in human tumour progression?. Cancer Surv. 1995; 24:19-42. View

10.

Thalmann G, Sikes R, Devoll R, Kiefer J, Markwalder R, Klima I . Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999; 5(8):2271-7. View

11.

Wang S, Bourguignon L . Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006; 132(1):19-24. DOI: 10.1001/archotol.132.1.19. View

12.

Katagiri Y, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K . CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999; 59(1):219-26. View

13.

Bourguignon L, Iida N, Zhu H, Young L, Muller W, Cardiff R . CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol. 1998; 176(1):206-15. DOI: 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3. View

14.

Desai B, Ma T, Chellaiah M . Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. J Biol Chem. 2008; 283(20):13856-66. PMC: 2376228. DOI: 10.1074/jbc.M709401200. View

15.

Williams K, Motiani K, Giridhar P, Kasper S . CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood). 2013; 238(3):324-38. PMC: 11037417. DOI: 10.1177/1535370213480714. View

16.

Cao G, Savani R, Fehrenbach M, Lyons C, Zhang L, Coukos G . Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol. 2006; 169(1):325-36. PMC: 1698758. DOI: 10.2353/ajpath.2006.060206. View

17.

Weber G, Ashkar S, Glimcher M, CANTOR H . Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996; 271(5248):509-12. DOI: 10.1126/science.271.5248.509. View

18.

Heider K, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P . A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol. 1993; 120(1):227-33. PMC: 2119493. DOI: 10.1083/jcb.120.1.227. View

19.

Zeilstra J, Joosten S, van Andel H, Tolg C, Berns A, Snoek M . Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene. 2013; 33(5):665-70. DOI: 10.1038/onc.2012.611. View

20.

Rudzki Z, Jothy S . CD44 and the adhesion of neoplastic cells. Mol Pathol. 1997; 50(2):57-71. PMC: 379585. DOI: 10.1136/mp.50.2.57. View